Stansberry Venture Technology is an investment analysis newsletter from Stansberry Research.
As part of a 2021 marketing campaign, Stansberry Research is highlighting a new investment opportunity linked to a major FDA announcement recently released by the FDA. Stansberry Research claims that announcement is “a massive opportunity” for investors.
What is the massive opportunity discussed by the Stansberry Venture Technology team? Should you subscribe to Stansberry Venture Technology? Keep reading to discover everything you need to know about Stansberry Venture Technology and how the subscription works.
What is Stansberry Venture Technology?
Stansberry Venture Technology is a financial newsletter published monthly by Stansberry Research.
Each month, the Stansberry Venture Technology team releases new investment opportunities, stock recommendations, and market analyses to subscribers.
By subscribing to Stansberry Venture Technology today, you can purportedly take advantage of a “massive opportunity” linked to a recent FDA announcement.
According to Stansberry Venture Technology, the team’s latest recommended company “could soon produce the biggest drug in history.” If you invest in that company today, your investment “could climb 250% in the coming months.”
By subscribing to Stansberry Venture Technology today, you can discover the name of this new company – and the names of three other companies “with 1,000% potential gains,” according to the Stansberry Venture Technology team.
A one-year subscription to Stansberry Venture Technology is priced at $5,000. As part of the new 2021 promotion, you can subscribe to the newsletter for $2,500 for your first year.
What is the Major FDA Announcement Investment Opportunity?
As part of a 2021 promotion, the Stansberry Research team is highlighting a new investment opportunity linked to a recent FDA announcement. The FDA has recently announced a breakthrough. Because of that breakthrough, 42% of Americans suffer from a disease that can now be cured. By investing in the company that makes that cure today, you can purportedly make big gains.
In fact, the Stansberry Venture Technology team claims you could earn 250% in the next few months by investing in this company today.
Here’s how Stansberry Research introduces the new investment opportunity:
“One U.S. government agency just completely changed American healthcare. That’s according to one of the most well-connected men in biotech research. His track record in the stock market is unmatched. Over the past 6 years, he’s made 39 winning recommendations, including one as high as 1,184%.”
Since 2015, that analyst has purportedly recommended stocks that have made gains of 100% to 1,184%. His recommendations have included depression drug makers, cancer drug companies, video game corporations, cholesterol drug makers, and a chip company, among others.
According to Stansberry Research, 54% of that analyst’s picks have made gains for readers who take his advice. That analyst has picked some of the most successful pharmaceutical companies of the last two decades.
Now, that analyst has spotted a new opportunity linked to a new, FDA-approved cure for multiple health crises, including obesity, fatty liver disease, and other health conditions.
The Disease Killing 42% of Americans is Obesity
After working your way through the Stansberry Research video and sales page, you discover the point: the mysterious disease killing 42% of Americans is obesity. 42% of Americans are obese, and people who are obese have a significantly higher risk of developing diseases, illnesses, and life-threatening conditions.
Now, one company has developed a cure for obesity. By subscribing to Stansberry Venture Technology today, you can discover the name of the company that has developed the cure – and the reasons to invest in that company today.
42% of Americans suffer from obesity. If a company was able to develop a drug that targeted obesity, it could quickly become one of the most successful drugs in the pharmaceutical industry. The Stansberry Venture Technology team claims to have identified one company that has developed a powerful anti-obesity drug. Investors who buy shares of that company today could earn huge returns on investment.
What Are the New FDA Approved Drugs?
Stansberry Venture Technology is highlighting several investment opportunities related to drugs recently approved by the FDA.
By investing in the companies that make these drugs today, investors could potentially earn huge returns on investment, according to the Stansberry Research team. Some of the opportunities and drugs highlighted by the team include:
Drug #1: Stop the Obesity Pandemic
The most-prescribed FDA-approved drug for weight loss is called Contrave. However, Stansberry Research claims an upcoming drug is even more effective than Contrave, and that’s why they’re bullish on the company that makes the drug. According to Stansberry Research, the new weight loss drug is effective across multiple weights, age groups, and other demographics. In one trial, patients lost 37 pounds, on average, without major surgery. One patient lost 80 pounds in 5 months after taking the drug.
Drug #2: Stop the Sickest from Dying
Another drug created by a company recommended by the Stansberry Venture Technology can purportedly stop the sickest from dying. The drug targets fatty liver disease, reducing the risk of dying from the disease. In a phase two trial cited on the Stansberry Venture Technology website, 100% of patients responded to the drug, to some degree, and 100% of patients lost some or most of their liver fat. In a placebo group, 0.3% of patients lost fat in their liver or almost none.
Stansberry Research claims investors have been looking for companies to solve these issues for 38 years. After many failed attempts, the two companies creating the drugs listed above have finally created the solution. That’s why the Stansberry Venture Technology team is confident that investing in these companies today could lead to huge returns in the future.
For all of these reasons, the Stansberry Venture Technology team believes this is “the right moment for 3 x 1,000% gains.” By investing in one or more of these drug companies today, investors could reap huge returns on investment.
What Will You Learn in Stansberry Venture Technology?
By subscribing to Stansberry Venture Technology today, you get access to a bundle of reports highlighting new FDA-approved drug advances made by several publicly traded companies. Investors also get access to regular portfolio updates, future reports and analyses, and more.
Stansberry Venture Technology is led by David Lashmet, the editor. The newsletter also features input from analysts John Engel and Bill McGilton. Together the three aim to identify new trends in the world of emerging technologies – and how investors could take advantage.
Here’s how Stansberry Research explains Stansberry Venture Technology:
“In Stansberry Venture Technology, Dave Lashmet scours the public markets for little-known, small-cap companies that are producing the next wonder drug or technology. And you can access these opportunities even if you’re not a millionaire or a venture capitalist.”
The newsletter is led by Dave Lashmet. Dave isn’t just an investment analyst: he’s an inventor with three active patents. Dave has developed, packaged, and sold his ideas to one of the largest consumer electronic firms in the world. In Stansberry Venture Technology, Dave uses his experience in the world of science and technology to highlight new and exciting developments – and how they impact investors.
Dave’s goal, with Stansberry Venture Technology, is to identify small and promising firms developing breakthrough treatments in the world of drugs, science, and technology.
In fact, Dave and his team have a specific goal: to help investors earn 500% to 1,000% returns on investments through their recommendations:
“….in Stansberry Venture, Dave is searching for the smallest and most promising firms out there… ones you’d likely never hear about (that is, until they get acquired). The goal is for subscribers to make five or 10 times their money on these speculations.”
Today, the Stansberry Venture Technology team holds approximately 15 to 25 positions. Most of these positions are considered very speculative. While other Stansberry Research newsletters focus on conservative investments, Stansberry Venture Technology focuses on higher-risk, higher-reward investments.
Stansberry Research recommends following the Stansberry Venture Technology investment recommendations with a minimum of $50,000 of capital to invest. They also recommend holding stocks for 12 months to 3 years or longer.
What’s Included with Stansberry Venture Technology?
As part of a 2021 promotion, all new subscriptions to Stansberry Venture Technology come bundled with bonus reports and more.E
Here’s what you get with each new subscription to Stansberry Venture Technology:
12 Monthly Issues of Stansberry Venture Technology
Each month, you receive a new issue of Stansberry Venture Technology on the fourth Tuesday. Each issue covers market news and analysis, new stock recommendations, and more. As of June 2021, Stansberry Venture Technology has more than 30 open recommendations. Each issue gives an update on new recommendations, making it easier for investors to make smart decisions.
Instant Access to Model Portfolio
All Stansberry Venture Technology subscribers receive access to the team’s model portfolio, which lists the entry points and exit points for each stock, the amount allocated to each stock, and more. By tracking this model portfolio, you can earn similar returns to the Stansberry Venture Technology team.
The Triple Play: Three 1,000% Obesity Drug Companies
This report discusses the names and ticker symbols of three drug companies that, according to the Stansberry Venture Technology team, have “1,000% potential.” The report explains the science behind each drug and why those drugs are effective, why Dave expects an upcoming FDA decision for each drug, and the entry point Dave recommends paying for shares in each drug company. You can discover everything you need to know about the three drug companies – and why investors could potentially earn 1,000% returns by investing in those companies today.
Bonus Report #1: A New Type of Energy Company…With 500% Gain Potential
In this report, the Stansberry Venture Technology team mentions the name and ticker symbol of a new energy company. By investing in that energy company today, investors can purportedly make 500% gains. The energy company specializes in geothermal technology. Dave predicts up to 500% gains on the small company because of its innovative technology.
Bonus Report #2: The Universal Cancer Cure
The first company that cures cancer will be one of the world’s most valuable firms. In this report, the Stansberry Venture Technology team discusses everything you need to know about a new cancer breakthrough, including the names and ticker symbols of several cancer-fighting companies that Dave and the team are excited about. Dave believes the stocks he recommends in this guide “could return several hundred percent (or more) in the coming years,” based on their analysis.
Email Updates on Breaking Opportunities
If Dave and the Stansberry Venture Technology team spot a new investment opportunity, they’ll send an email alert to subscribers discussing that opportunity. Subscribers never have to miss an opportunity.
How Much Money Can You Make with Stansberry Venture Technology?
The Stansberry Venture Technology website is filled with stories of customers earning huge returns on investment by following the investment recommendations provided by Dave and his team at Stansberry Venture Technology.
The goal of the email newsletter is to help investors earn 5x to 10x returns on investment or 500% to 1,000% returns.
Here are some of the earnings claims made on the Stansberry Venture Technology sales page, according to real investors and subscribers:
One investor, John W., claims he is up $8,000 so far on just one recommendation from Dave and his team; he praises Dave for having his finger on the pulse of biotech
Another customer, Bob P., claims he earned $7,900 on just one of Dave’s investment recommendations; that man invested those profits in several more recommendations, and he claims he is up “on all of them”
One man claims he was recently diagnosed with cancer, and he decided to follow Dave’s investment recommendations; that man claims he has earned 100% gains from Dave’s recommendations, including one biotech company that makes the same machine used in his cancer treatment
Like other investment newsletters marketed online today, Stansberry Venture Technology is marketed as a way for investors to quickly earn sizable returns on investment. The official Stansberry Venture Technology website is filled with claims of investors earning huge returns on investment by following Dave’s recommendations in the biotech space and outside of it.
Stansberry Venture Technology Pricing
Stansberry Venture Technology is priced at $2,500 for your first year when subscribing through the new online promotion.
Normally, each year is priced at $5,000. After your first year, Stansberry Research will renew your subscription at the normal price of $5,000 per year. You will receive an alert before your subscription is renewed, and you can cancel your subscription at any time.
Stansberry Venture Technology Refund Policy
Stansberry Venture Technology subscriptions are non-refundable. You cannot obtain a refund on your subscription after completing the payment.
If you are unhappy with your subscription to Stansberry Venture Technology for any reason, or if you did not make triple-digit returns through the recommended investments, then you cannot obtain a refund for any reason.
About Stansberry Research
Stansberry Research is a financial publishing firm found online. The company has 500,000 worldwide subscribers and 70,000 lifetime subscribers. The Stansberry Research team also has 175+ years of combined analyst experience.
In addition to offering the Stansberry Venture Technology newsletter, the company offers newsletters like Stansberry’s Investment Advisory, True Wealth, Retirement Millionaire, and Stansberry Innovations Report, among other free and paid newsletters.
You can contact the Stansberry Venture Technology team via the following:
- Email: email@example.com
- Phone: (888) 261-2693
Stansberry Venture Technology Final Word
Stansberry Venture Technology is a financial newsletter published by Stansberry Research. The newsletter aims to identify new investment opportunities in expanding areas of tech and science.
As part of a 2021 marketing campaign, the Stansberry Venture Technology team has launched a marketing campaign featuring new investment opportunities related to recent FDA approvals. According to the Stansberry Venture Technology team, you could earn 250% to 1,000% returns by investing in their recommended stocks today.
To learn more about Stansberry Venture Technology and the firm’s new investment opportunities, visit online today.
The links contained in this product review may result in a small commission if you opt to purchase the product recommended at no additional cost to you. This goes towards supporting our research and editorial team and please know we only recommend high quality products.
Please understand that any advice or guidelines revealed here are not even remotely a substitute for sound medical advice from a licensed healthcare provider. Make sure to consult with a professional physician before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary as the statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease.